Abstract: Disclosed in a method of treating a myeloid neoplasm, acute leukemia, or infectious disease in a subject, the method including administering to a subject in need thereof a pegylated interferon-? at a regular interval of every 2 to 8 weeks at a first dose of 250 to 500 ?g.

Abstract: A pegylated type I interferon for use in treating an infectious disease, cancer, or myeloproliferative disease in a subject in need thereof, wherein a 50 to 540 ?g dose of the pegylated type I interferon is administered to the subject at a regular interval for a treatment period, the interval being 3 to 8 weeks.

Abstract: The present disclosure includes an improved method of making a protein. The steps and conditions were described and carried out with significantly improved protein yield, thereby reducing manufacturing cost.

Abstract: Provided is a method for preventing or treating a liver disease, including administering a therapeutically effective amount of pharmaceutical composition to a subject in need, and the pharmaceutical composition includes the isothiocyanate structural modified compound and a pharmaceutically acceptable carrier thereof.

Abstract: Described is a method for treating an infectious disease, cancer, or myeloproliferative disease in a subject, wherein a 50 to 540 ?g dose of a pegylated type I interferon is administered to the subject at a regular interval for a treatment period, the interval being 3 to 8 weeks.

Abstract: Disclosed in a method of treating a myeloid neoplasm, acute leukemia, or infectious disease in a subject, the method including administering to a subject in need thereof a pegylated interferon-? at a regular interval of every 2 to 8 weeks at a first dose of 250 to 500 ?g.

Abstract: Described herein is a method of treating chronic myeloid leukemia in a subject including administering to a subject in need thereof a pegylated interferon-? and a BCR-ABL tyrosine kinase inhibitor simultaneously or sequentially.

Abstract: A pegylated type I interferon for use in treating an infectious disease, cancer, or myeloproliferative disease in a subject in need thereof, wherein a 50 to 540 ?g dose of the pegylated type I interferon is administered to the subject at a regular interval for a treatment period, the interval being 3 to 8 weeks.

Abstract: A method of reducing TET2 mutant allele burden in a subject, comprising: administering to a subject identified as having a TET2 mutation a 50 to 540 ?g dose of a pegylated interferon-? at a regular interval of 2 to 8 weeks for a treatment period, the pegylated interferon-? being a conjugate of formula I: in which each of R1, R2, R3, R4, and R5, independently, is H, C1-5 alkyl, C2-5 alkenyl, C2-5 alkynyl, aryl, heteraryl, C3-8 cycloalkyl, or C3-8 heterocycloalkyl; each of A1 and A2, independently, is a polymer moiety; each of G1, G2, and G3, independently, is a bond or a linking functional group; P is an interferon-? moiety; m is 0 or an integer of 1-10; and n is an integer of 1-10, wherein the subject has a reduction in TET2 mutant allele burden at a second time point in the treatment period as compared to a first time point before or earlier in the treatment period.

Abstract: A method of treating a myeloid neoplasm in a subject, the method comprising administering to a subject in need thereof a 50 to 500 ?g dose of a pegylated interferon-? once every 2 to 8 weeks, the pegylated interferon-? being a conjugate of formula I: in which each of R1, R2, R3, R4, and R5, independently, is H, C1-5 alkyl, C2-5 alkenyl, C2-5 alkynyl, aryl, heteraryl, C3-8 cycloalkyl, or C3-8 heterocycloalkyl; each of A1 and A2, independently, is a polymer moiety; each of G1, G2, and G3, independently, is a bond or a linking functional group; P is an interferon-? moiety; m is 0 or an integer of 1-10; and n is an integer of 1-10; wherein the subject has a complete molecular response, the complete molecular response including a JAK2617F allele burden below 1%.

Abstract: A pegylated type I interferon for use in treating an infectious disease, cancer, or myeloproliferative disease in a subject in need thereof, wherein a 50 to 540 ?g dose of the pegylated type I interferon is administered to the subject at a regular interval for a treatment period, the interval being 3 to 8 weeks.

Abstract: This invention relates to a process of synthesizing a ?-nucleoside compound of formula (I): wherein R1 is alkyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl. The process includes reacting a compound of formula (II): with a compound of formula (III): wherein R1 is as defined above and X is chloride, bromide, iodide, methanesulfonate, triflate, p-toluenesulfonate, trifluoroacetate, 4-nitrophenoxy, or N-succinimidyloxy, in a solvent and in the presence of a base.

Abstract: This invention relates to use protein-polymer conjugates described in the specification to treat various diseases, including disease is idiopaic myelofibrsis, polycythaemia vera, and essential thromobocythaemia.

Abstract: This invention relates to a conjugate of a polymer moiety and an interferon-? moiety, an erythropoietin moiety, or a growth hormone moiety.

Abstract: Protein-polymer conjugates are described. Also described are a method for preparing a protein-polymer conjugate and its use in treating hepatitis B virus or hepatitis C virus infection.

Abstract: This invention relates to use protein-polymer conjugates described in the specification to treat various diseases, including disease is idiopaic myelofibrsis, polycythaemia vera, and essential thromobocythaemia.

Abstract: This invention relates to a conjugate of a polymer moiety and an erythropoietin moiety.

Abstract: This invention relates to a conjugate of a polymer moiety and an interferon-? moiety, an erythropoietin moiety, or a growth hormone moiety.

Abstract: The invention is based on the discovery that compounds of Formula I are unexpectedly highly potent and selective inhibitors of the adenosine A1 receptor. Adenosine A1 antagonists can be useful in the prevention and/or treatment of numerous diseases, including cardiac and circulatory disorders, degenerative disorders of the central nervous system, respiratory disorders, and many diseases for which diuretic treatment is suitable.

Abstract: This invention relates to protein-polymer conjugates described in the specification. Also disclosed are a method for preparing a protein-polymer conjugate and its use in treating hepatitis B virus or hepatitis C virus infection.